Pfizer $1.9 Bil. Vicuron Acquisition Culminates Antibiotic Research Deal
Executive Summary
Pfizer's $1.9 bil. purchase of Vicuron marks the culmination of a six-year collaboration between the pharma giant and the biotech company to develop new antibiotic candidates
You may also be interested in...
Pfizer Infectious Disease Pipeline Spreads Roots In Competitive Areas
As Pfizer's infectious disease unit begins its recovery from the loss of exclusivity of the blockbuster Zithromax (azithromycin) in 2006 and Diflucan (fluconazole) in 2004, the company is repositioning the portfolio to focus on specialty diseases, particularly HIV and hepatitis C, Senior Director/Commercial Head-Infectious Disease Worldwide Pharmaceutical Operations Andrew Schmeltz said
Pfizer Infectious Disease Pipeline Spreads Roots In Competitive Areas
As Pfizer's infectious disease unit begins its recovery from the loss of exclusivity of the blockbuster Zithromax (azithromycin) in 2006 and Diflucan (fluconazole) in 2004, the company is repositioning the portfolio to focus on specialty diseases, particularly HIV and hepatitis C, Senior Director/Commercial Head-Infectious Disease Worldwide Pharmaceutical Operations Andrew Schmeltz said
Pfizer To Use Cash From Sale Of OTC Unit To J&J For Biotech, Specialty Deals
Pfizer will use the cash gained through the sale of its consumer unit to Johnson & Johnson to make targeted specialty pharma and biotech acquisitions, the firm said following announcement of the deal June 26